Hemostemix gets US patent entitled 'r...
Home  »  Community News  »  Hemostemix gets US p...
May
22
ragupathyrenganathan
Hemostemix gets US patent entitled ‘regulating stem cells’ for generating therapeutic cell products
Pharma News
0
, , ,

Hemostemix Inc., a clinical-stage autologous cell-therapy company, has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application 13/970,807 entitled “Regulating Stem Cells.”

The patent covers a method for generating therapeutic cell products, including the company’s lead product ACP-01, from a simple draw of peripheral blood, which is the flowing, circulating blood in the human body. The Hemostemix technology enables proprietary cells grown from a patient’s blood to be injected into that patient’s diseased tissue to support the formation of new blood vessels.

This patent, the third within the Hemostemix intellectual property estate that will be issued by the USPTO, is part of a broad technology platform now protected by more than 40 patents issued in major markets, including the United States, the European Union, Japan, and China. The company continues to actively file and prosecute patents around all aspects of its technology in support of its global commercialization plans.

“This Notice of Allowance is a significant building block of our intellectual property strategy, which is designed so that we can fully exploit the fundamental value of our ongoing research and development for ACP-01, both at our research and manufacturing facility in Ness Ziona, Israel, and via collaborations,” said Dr. Ina Sarel, vice president of research and development at Hemostemix.

“Receiving the Notice of Allowance helps pave the way for Hemostemix to expand into the US drug market,” said Dr Elmar Burchardt, president and CEO of Hemostemix. “With this patent, we have an important foundation for initiating clinical development activities in the U.S., as Hemostemix intends to submit an Investigational New Drug (IND) application to the US Federal Drug Administration (FDA) within the next few weeks.”

Previously on May 11, 2015, Hemostemix announced its engagement with Stonegate Capital Partners, Inc. for strategic investor relations services in the US institutional investment community. The engagement is for a term of 12 months, with a provision for early termination if required. The company will pay Stonegate US$5000 per month for its services for a minimum of three months.



Leave a reply

You must be logged in to post a comment.